| Original language | English (US) |
|---|---|
| Pages (from-to) | 6023-6027 |
| Number of pages | 5 |
| Journal | Blood Advances |
| Volume | 6 |
| Issue number | 23 |
| DOIs | |
| State | Published - Dec 13 2022 |
Bibliographical note
Funding Information:Conflict-of-interest disclosure: P.J.O. receives honoraria and consulting fees from Immusoft, Orchard Therapeutics, Avrobio, and Neurogene; and clinical trial support from Bluebird Bio. J.B.E. receives research support from Lysogene, Orchard Therapeutics, Sobi, and Takeda; and adboard honoraria and/or consulting from Amicus, Bluebird Bio, Denali Therapeutics, EcoR1, Orchard Therapeutics, JCR Pharmaceuticals, Regenxbio, Sanofi Genzyme, and Takeda. L.E.P. receives research support from BioMarin, Takeda, and Sobi; is a recipient of honoraria and consulting fees from Bio-Marin and Lysogene; and speaker’s fees for educational events for Sanofi Genzyme and BioMarin. L.M.P. is the Lead Director, Biochemical Genetics Laboratory at Greenwood Genetics. E.B. is a speaker for Sanofi/Genzyme and receives research support from BioMarin and Bluebird Bio. M.P. is the Section Chief of Biochemical Genetics at ARUP Laboratories. T.C.L. is a recipient of honoraria and consulting fees from Immusoft, Orchard Therapeutics, and Neurogene; and receives clinical trial support from Bluebird Bio. The remaining authors declare no competing financial interests.